Bruno Medeiros on How to Interpret AML Clinical Trial Data
In the emerging era of personalized treatment, it may be time to rethink which surrogate markers are used in AML clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - July 20, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Benefits and Challenges of Safer-Conception Counseling for HIV Serodiscordant Couples in Uganda
CONCLUSIONSCounseling can help HIV-infected individuals make informed choices about childbearing and safer-conception methods; however, a controlled clinical trial is needed to determine whether clients use such methods correctly and to assess rates of pregnancy and transmission. Policymakers need to consider including safer-conception counseling as part of routine HIV care. (Source: The Guttmacher Institute)
Source: The Guttmacher Institute - July 19, 2018 Category: International Medicine & Public Health Authors: Guttmacher Source Type: news

Recruitment for a pragmatic clinical trial to reduce fall injuries - Cauley JA.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - July 19, 2018 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Medtronic launches ECG belt HF optimization trial
Medtronic (NYSE:MDT) said today it launched a new clinical trial evaluating the use of its ECG belt research system as a diagnostic tool for improving cardiac resynchronization therapy for heart failure patients. The Fridley, Minn.-based company said it has enrolled the first patients in the trial at Des Moines, Iowa’s Mercy Medical Center – West Lakes by principal investigator Dr. Troy Hounshell. “The aim of this technology is to give physicians immediate feedback that may impact clinical decision making at the time of implant and also during follow-up visits. By pairing CRT with the ECG Belt, we ha...
Source: Mass Device - July 19, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Assist Devices Cardiovascular Clinical Trials Medtronic Source Type: news

Medical News Today: Potential new MS drug could regenerate myelin
A study finds that blocking the M3R receptor improves myelination in mice implanted with human progenitor cells, maybe leading to clinical trials in MS. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 19, 2018 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news

Advancing Research Needed to Develop a Universal Influenza Vaccine (R01 Clinical Trial Not Allowed)
Funding to support research activities that will advance NIAIDs mission to develop a universal influenza vaccine providing durable protection against multiple influenza strains, including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines. (Source: PHPartners.org)
Source: PHPartners.org - July 19, 2018 Category: International Medicine & Public Health Source Type: news

Arguing for Adaptive Clinical Trials in Sepsis
Sepsis is life-threatening organ dysfunction due to dysregulated response to infection. Patients with sepsis exhibit wide heterogeneity stemming from genetic, molecular, and clinical factors as well as differences in pathogens, creating challenges for the development of effective treatments. In this review, we discuss challenges in the evaluation of treatments for sepsis, and explore potential benefits and weaknesses of recent advances in adaptive trial methodologies to address these challenges. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - July 19, 2018 Category: Consumer Health News Source Type: news

Association of monthly high-dose vitamin D supplementation and cancer risk
This study analyzed data from a randomized clinical trial that included a placebo group. There were 328 total cases of   cancer, with 165 among 2,558 participants (6.5 percent) who received monthly high-dose vitamin D supplementation and 163 among 2,550 participants (6.4 percent) in the placebo group. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 19, 2018 Category: Cancer & Oncology Source Type: news

AF-CBT for families experiencing physical aggression or abuse served by the mental health or child welfare system: an effectiveness trial - Kolko DJ, Herschell AD, Baumann BL, Hart JA, Wisniewski SR.
The Partnerships for Families project is a randomized clinical trial to evaluate the effectiveness of Alternatives for Families: A Cognitive Behavioral Therapy (AF-CBT), an evidence-based treatment (EBT) for families who are at risk of or have histories of... (Source: SafetyLit)
Source: SafetyLit - July 19, 2018 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Medtronic Pumps Confidence in MiniMed Through Performance Guarantee
Medtronic has been leading the industry in the charge toward value-based care, and its efforts have been paying off in spades, as MD+DI has recently observed. Now, the company has found yet another way to stay ahead of the curve. The company recently launched a new performance guarantee program around its MiniMed 670G insulin pump. The new program is an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this guarantee, Medtronic said it will provide flat-fee reimbursements of up to $25,000 per pump over four years for qualifying diabetes-related inpatient ho...
Source: MDDI - July 18, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Endari (L-Glutamine) Supplement May Ease the Pain of Sickle Cell Disease
WEDNESDAY, July 18, 2018 -- An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows. Endari, a medicine-grade version of the dietary supplement L-glutamine, reduced sickle cell... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 18, 2018 Category: General Medicine Source Type: news

Supplement May Ease the Pain of Sickle Cell Disease
WEDNESDAY, July 18, 2018 -- An FDA-approved supplement reduces episodes of severe pain in people with sickle cell disease, a new clinical trial shows. Endari, a medicine-grade version of the dietary supplement L-glutamine, reduced sickle cell... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 18, 2018 Category: General Medicine Source Type: news

Medical News Today: Do omega-3 supplements really benefit the heart?
A major systematic review of clinical trials led by independent researchers finds 'little to no' evidence that omega-3 capsules benefit heart health. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 18, 2018 Category: Consumer Health News Tags: Heart Disease Source Type: news

Trial Adds Gemcitabine to Pleural Mesothelioma HIOC Therapy
Results of a phase I clinical trial highlight how the addition of a drug to an existing treatment option appears safe and may improve outcomes in certain patients with malignant pleural mesothelioma (MPM). The primary goal of the trial was to determine the maximum tolerated dose of gemcitabine added to cisplatin when these drugs are delivered together as heated intraoperative chemotherapy (HIOC) during surgery. Researchers have studied cisplatin alone for HIOC. The addition of gemcitabine — a chemotherapy drug often used to treat pancreatic, ovarian and breast cancers — is new. The Journal of Thoracic Oncology...
Source: Asbestos and Mesothelioma News - July 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Diet and Physical Activity Assessment Methodology (R01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. (Source: PHPartners.org)
Source: PHPartners.org - July 18, 2018 Category: International Medicine & Public Health Source Type: news

Diet and Physical Activity Assessment Methodology (R21 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages innovative research to enhance the quality of measurements of dietary intake and physical activity. (Source: PHPartners.org)
Source: PHPartners.org - July 18, 2018 Category: International Medicine & Public Health Source Type: news

Using adrenaline in cardiac arrests results in less than 1 percent more people leaving hospital alive
(University of Warwick) A clinical trial of the use of adrenaline in cardiac arrests has found that its use results in less than 1 percent more people leaving hospital alive -- but almost doubles the risk of severe brain damage for survivors of cardiac arrest. The research raises important questions about the future use of adrenaline in such cases and will necessitate debate amongst healthcare professionals, patients and the public. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2018 Category: International Medicine & Public Health Source Type: news

UA clinical trial to repurpose ketamine for Parkinson's patients
(University of Arizona Health Sciences) A decades-old drug known as ketamine is being repurposed to potentially help Parkinson's patients in a new clinical trial at the UA College of Medicine -- Tucson. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 18, 2018 Category: International Medicine & Public Health Source Type: news

Do stress balls or hand holding reduce anxiety during skin cancer surgery?
(JAMA Network) Exploring whether hand-holding or squeezing a stress ball would reduce patient anxiety during skin cancer surgery under local anesthesia was the main focus of this randomized clinical trial. The study of 135 patients at an urban academic medical center reports that patients who used stress balls or whose hands were held weren't less anxious, didn't experience less pain and were no more satisfied with the procedure than other patients. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 18, 2018 Category: International Medicine & Public Health Source Type: news

It ’s Nearly Impossible to Diagnose Alzheimer’s Disease in Living People. Bill Gates Wants to Change That
Name practically any disease or condition that afflicts the human body and there’s probably a good test for detecting it — preferably early, when there’s a chance that promising treatments can slow it down or even cure it. Cancer, inherited forms of heart disease, diabetes, hypertension, and even certain mental illnesses can be picked up by tracking hormones, genes or other things circulating in the body. But that hasn’t been the case with Alzheimer’s disease, the neurodegenerative condition that was first described in 1906, and more than a century later, still doesn’t have a blood test ...
Source: TIME: Health - July 17, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Disease healthytime onetime Source Type: news

Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy
Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma. The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of its ABPA therapy in the fourth quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy appeared first on ...
Source: Mass Device - July 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Wall Street Beat Pulmatrix Inc. Source Type: news

Broadly acting antibodies found in plasma of Ebola survivors
(NIH/National Institute of Allergy and Infectious Diseases) Recent Ebola virus disease (EVD) outbreaks highlight the need for licensed treatments. ZMapp, an experimental therapy, has shown promise in a clinical trial, but targets only one of five known species of Ebola virus. Now NIAID-supported scientists have discovered powerful, broadly neutralizing antibodies (bNAbs) in the blood of EVD survivors. In animal studies, two of these antibodies provided substantial protection against disease caused by the three species known to cause fatal human illness. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 17, 2018 Category: Infectious Diseases Source Type: news

Why investors injected $62 million into a Peninsula biotech targeting a deadly lung disease
Pliant Therapeutics expects to have 50 employees by the end of the year and is recruiting for its first clinical trial. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 16, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

Cerapedics raises $22m
Cerapedics said late last week it closed a $22 million round of financing and added three new members to its board of directors The funding round was led by family investment fund KCK Group, the Westminster, Colo.-based company said, and will help support the company’s bone graft products. “We are pleased to announce that we have successfully completed an equity financing that will continue to accelerate the commercial release of i-Factor Peptide enhanced bone graft and support the execution of a second Level I investigational device exemption human clinical study that will broaden our market indication in...
Source: Mass Device - July 16, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Orthopedics Cerapedics Inc. Source Type: news

BMS ’ Opdivo/Yervoy combo cleared for kidney cancer
Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.07/16/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 16, 2018 Category: Urology & Nephrology Source Type: news

Why investors injected $62 million into a Peninsula biotech targeting a deadly lung disease
Pliant Therapeutics expects to have 50 employees by the end of the year and is recruiting for its first clinical trial. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 16, 2018 Category: Health Management Authors: Ron Leuty Source Type: news

Research explores link between mental health and rheumatoid arthritis
 A new study has gone further towards ensuring people living with both rheumatoid arthritis and mental health problems get the best treatment for them.Rheumatoid arthritis affects the whole body, but we know that it can also have an impact on a person’s mental health. Around a third of the 400,000 people in the UK with rheumatoid arthritis also experience mental health issues. This compares to around 1 in 4 people in the general population.The way rheumatoid arthritis is treated was revolutionised by the discovery of anti-TNF drugs– now widely used in medical practice. Better treatments have led to more pe...
Source: Arthritis Research UK - July 15, 2018 Category: Rheumatology Source Type: news

The eye doctor who could not see the stars
Dr Andrew Bastawrous has invented an app that has been shown in clinical trials to help more children see clearly. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 14, 2018 Category: Consumer Health News Source Type: news

Innovation Depot firm lands major partnership with UAB
XpertDox, an Innovation Depot data analytics firm focused on improving health care for people with rare and serious diseased, confirmed the University of Alabama at Birmingham has selected the company ’s XpertTrial platform to improve clinical trial enrollment timelines and accelerate patient recruitment for medical research. The goal of this collaboration is to promote access to promising clinical studies while improving outcomes for patients and clinicians. Financial terms of the deal were n ot… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 13, 2018 Category: Biotechnology Authors: Tyler Patchen Source Type: news

Innovation Depot firm lands major partnership with UAB
XpertDox, an Innovation Depot data analytics firm focused on improving health care for people with rare and serious diseased, confirmed the University of Alabama at Birmingham has selected the company ’s XpertTrial platform to improve clinical trial enrollment timelines and accelerate patient recruitment for medical research. The goal of this collaboration is to promote access to promising clinical studies while improving outcomes for patients and clinicians. Financial terms of the deal were n ot… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 13, 2018 Category: Health Management Authors: Tyler Patchen Source Type: news

RenovoRx sets its sights on localized treatment of pancreatic cancer
People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter could help usher in a targeted treatment option for these patients. The company’s RenovoCath dual-balloon infusion catheter is designed to localize the delivery of chemotherapy to a pancreatic tumor, eliminating the need for systemic chemothe...
Source: Mass Device - July 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Catheters Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Oncology Pharmaceuticals RenovoRx Source Type: news

Health Canada ordered to release confidential drug company data on HPV vaccines
A Federal Court judge has ordered Health Canada to release to an American researcher reams of clinical trial data on five medications, undercutting the federal government’s attempts to keep the information confidential. (Source: CBC | Health)
Source: CBC | Health - July 13, 2018 Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news

Drug Combination Boosts Older Adults' Immunity in Early Trial Drug Combination Boosts Older Adults' Immunity in Early Trial
A phase 2a randomized, placebo-controlled clinical trial showed that a combination of drugs decreases the incidence of infections, including influenza and pneumonia, in older adults.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2018 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Sanuwave Health, HyperMed partner for DermaPace diabetic foot ulcer study
Sanuwave Health (OTC:SNWV) said yesterday it is partnering with HyperMed to sponsor a clinical investigation exploring Sanuwave’s DermaPace system designed for treating diabetic foot ulcers. The joint study will look to quantify the level of increased perfusion and oxygenation during and after treatment with the DermaPace, Suwanee, Ga.-based Sanuwave said. The study will use HyperMed’s Hyperview spectral imaging device to measure oxygen saturation, oxyhemoglobin levels and deoxyhemoglobin levesl in superficial tissue. Sanuwave said that an initial case series in the study will be performed at two sites, Ne...
Source: Mass Device - July 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Clinical Trials Regenerative Medicine Wound Care SANUWAVE Health Inc. Source Type: news

The Recommended Dose podcast - JAMA Internal Medicine's Rita Redberg
This week influential Editor-in-Chief ofJAMA Internal Medicine Dr Rita Redberg joins host Ray Moynihan on Cochrane Australia's podcastThe Recommended Dose to share a wide ranging conversation on all things health. A Professor at the University of California San Francisco and high profile contributor to The Washington Post and New York Times, Rita is also a practising cardiologist who loves to see patients. She says that ‘being a doctor is really a privilege’.Together, Ray and Rita canvas many topics including shared decision making between doctors and patients, the tricky territory of medical device a...
Source: Cochrane News and Events - July 12, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

The Recommended Dose podcast - JAMA Internal Medicine's Rita Redberg
This week influential Editor-in-Chief ofJAMA Internal Medicine Dr Rita Redberg joins host Ray Moynihan on Cochrane Australia's podcastThe Recommended Dose to share a wide ranging conversation on all things health. A Professor at the University of California San Francisco and high profile contributor to The Washington Post and New York Times, Rita is also a practising cardiologist who loves to see patients. She says that ‘being a doctor is really a privilege’.Together, Ray and Rita canvas many topics including shared decision making between doctors and patients, the tricky territory of medical device a...
Source: Cochrane News and Events - July 12, 2018 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique
Large pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach. “What we’ve come up with is a very innovative nasal spray, which when sprayed into the nose penetrates the naval cavity quite rapidly, binds to the [nicotinic acetylcholine] receptors, and can actually stimulate the patient’s natural tear production,” CEO Jeffrey Nau told Drug Delivery Bu...
Source: Mass Device - July 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Allergan oysterpointpharma Source Type: news

Live Longer or Better? Live Longer or Better?
The cancer clinical trial paradigm will be improved with the incorporation of palliative care.Medscape Nurses (Source: Medscape Nurses Headlines)
Source: Medscape Nurses Headlines - July 12, 2018 Category: Nursing Tags: Nursing Viewpoint Source Type: news

Determinants of antidepressant response: implications for practice and future clinical trials - Rabinowitz J, Werbeloff N, Mandel FS, Marangell L, Menard F, Kapur S.
BACKGROUND: Response to antidepressants in major depressive disorder is variable and determinants are not well understood or used to design clinical trials. We aimed to understand these determinants. METHODS: Supported by Innovative Medicines Initi... (Source: SafetyLit)
Source: SafetyLit - July 12, 2018 Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news

Proton Therapy Trials'at Risk,' Slow to Enroll Patients Proton Therapy Trials'at Risk,' Slow to Enroll Patients
Is proton therapy better than standard radiotherapy in the treatment of cancer? Seven major randomized clinical trials have no answers at this point.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Powdered insulin to prevent type-1 diabetes in children
A new clinical trial will investigate if giving powdered insulin to babies at high risk of developing type-1 diabetes can be a solution to prevent the disease.BBC News (Source: Society for Endocrinology)
Source: Society for Endocrinology - July 12, 2018 Category: Endocrinology Source Type: news

Potential new surgical options for women with multiple ipsilateral breast cancer
(Dartmouth-Hitchcock Medical Center) Initial results of a new national clinical trial show that the majority of women with breast cancer who have two to three sites of disease in a single breast at the time of diagnosis are able to successfully complete breast-conserving surgery without conversion to mastectomy. This is the first prospective study to assess this possibility, and its findings improve the surgical choices available to women with multiple ipsilateral breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2018 Category: Cancer & Oncology Source Type: news

Medtronic ’s HVAD System Just Became Less Invasive
Medtronic has gained FDA approval for a less-invasive implant approach of its HVAD System, a left ventricular assist device (LVAD) for advanced heart failure patients. The Dublin-based company picked up the technology when it acquired HeartWare in 2016. The firm said the technology is the only LVAD approved in the U.S. for implant via thoracotomy, a small lateral, surgical incision between the patient's ribs on the left side of the chest. FDA approval for HVAD implantation via thoracotomy is based on data from the LATERAL prospective clinical trial, in which 144 patients, with end-stage heart failure who were eligible for ...
Source: MDDI - July 12, 2018 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Business Source Type: news

Trauma foam could quickly stop internal bleeding, researchers say
The FDA has approved a clinical trial of trauma foam in patients at a Boston hospital. Researchers believe it could help save lives. CBS Boston's Louisa Moller reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 11, 2018 Category: Consumer Health News Source Type: news

Don't dismiss tech solutions to mental health problems
There is a desperate shortage of skilled clinicians to treat mental health disorders. Our study shows how virtual reality could fill the gapThe words “mental health” and “crisis” now appear to be yoked together. About a quarter of us willsuffer from a clinical psychological disorder over the next year, but most peoplewill receive no help at all. The question is no longer about whether we have a problem, but what we are going to do about it.We don ’t lack high-quality, evidence-based psychological treatments for many mental health problems. These treatments have beenverified by dozens of clinic...
Source: Guardian Unlimited Science - July 11, 2018 Category: Science Authors: Daniel Freeman and Jason Freeman Tags: Mental health Psychology Science Artificial intelligence (AI) Consciousness Neuroscience Computing Technology Society Virtual reality Source Type: news

FDA Approves HeartWare LVAD for Implant via Thoracotomy FDA Approves HeartWare LVAD for Implant via Thoracotomy
Implanting Medtronic's HeartWare ventricular assist device via the less invasive approach was shown to be safe and effective in the LATERAL clinical trial.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 11, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Trial of anti-ageing drugs that rejuvenate immune system hailed a success
Most middle aged adults could benefit from a short term treatment to revitalise the immune system and organs that deteriorate with age, say researchersScientists have hailed the success of a clinical trial which found that experimental anti-ageing drugs may protect older people from potentially fatal respiratory infections by rejuvenating their immune systems.In a trial involving people aged 65 and over, those who received a combination therapy of two anti-ageing compounds reported nearly half the number of infections over the following year as a control group who received only placebos.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 11, 2018 Category: Science Authors: Layal Liverpool Tags: Science Ageing Medical research Immunology Biochemistry and molecular biology Health Source Type: news

Improving blood flow to fight disease: Whole-body vibration therapy found to increase blood and oxygen delivery
(Natural News) A meta-analysis published in the African Journal of Traditional, Complementary and Alternative Medicines revealed that whole-body vibration exercise (WBVE) may significantly improve blood flow kinetics and boost oxygen delivery across the body, making it a viable treatment for a variety of degenerative diseases. The researchers pooled data from up to seven clinical trials and studies as part of... (Source: NaturalNews.com)
Source: NaturalNews.com - July 11, 2018 Category: Consumer Health News Source Type: news

Medtronic & #039;s Value-Based Partnerships are Paying Off in Spades
Dublin, Ireland-based Medtronic continues to lead the charge toward value-based care, and it's beginning to pay off in a big way.  One of the company's value-based care partners, UnitedHealthcare, has seen a 27% decline in the rate of preventable hospital admissions for Medtronic insulin pump users compared to patients on multiple daily insulin injections, according to an analysis of more than 6,000 members with diabetes on Medtronic MiniMed 630G and previous generation insulin pumps. And that's just in the first year of the partnership. The analysis included a mix of members using both standalone insulin pumps and pu...
Source: MDDI - July 11, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Medtronic wins FDA nod for thoracotomy-based HVAD procedure
Medtronic (NYSE:MDT) said today it won FDA approval for thoracotomy-based implantation procedures with its HVAD left ventricular assist device, which it said is a less-invasive implantation approach. The Fridley, Minn.-based medtech giant touted the approval as the first for any commercially available LVAD in the US, and said that the clearance came based on data from the Lateral clinical trial of the device. The 44-patient trial met its primary endpoint of non-inferiority, with data indicating an 88.1% rate of survival at six months free from disabling stroke or device explant or exchange due to malfunction. Results ...
Source: Mass Device - July 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Medtronic Source Type: news